Search results for "natural-history"

showing 10 items of 10 documents

Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

2018

PubMed: 29599078

0301 basic medicineBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences.HBsAgPediatricsDelphi TechniqueInfectious Disease TransmissionCHRONIC HBV INFECTION ; NATURAL-HISTORY ; FOLLOW-UP ; HBSAG ; CARRIERS ; AGE ; COUNTRIES ; DISEASE ; ANTIGEN ; COHORTddc:616.07Global Healthmedicine.disease_causeDISEASE0302 clinical medicinePrevalenceHBVChildddc:616Antiviral Agents/therapeutic useeducation.field_of_studyBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti.Chronic/drug therapy/epidemiology/prevention & control/transmissionGastroenterologyHepatitis B Surface Antigens/bloodHepatitis BCARRIERSHepatitis B10219 Clinic for Gastroenterology and HepatologyChild Preschool030211 gastroenterology & hepatologyViral hepatitisViral loadCOUNTRIESAdultmedicine.medical_specialtyHepatitis B vaccineANTIGENPopulation610 Medicine & healthAntiviral AgentsMass VaccinationHepatology; Gastroenterology03 medical and health sciencesHepatitis B ChronicHBSAGAGESDG 3 - Good Health and Well-beingmedicineHumansCOHORT2715 GastroenterologyPreschooleducationDisease burdenHepatitis B virusHepatitis B Surface AntigensHepatologybusiness.industryViral VaccinesNATURAL-HISTORYmedicine.diseaseInfectious Disease Transmission VerticalCHRONIC HBV INFECTIONVertical/prevention & control030104 developmental biology2721 HepatologyHuman medicineFOLLOW-UPbusiness
researchProduct

Multiple sclerosis severity score: Using disability and disease duration to rate disease severity

2005

Background: There is no consensus method for determining progression of disability in patients with multiple sclerosis (MS) when each patient has had only a single assessment in the course of the disease. Methods: Using data from two large longitudinal databases, the authors tested whether cross-sectional disability assessments are representative of disease severity as a whole. An algorithm, the Multiple Sclerosis Severity Score (MSSS), which relates scores on the Expanded Disability Status Scale (EDSS) to the distribution of disability in patients with comparable disease durations, was devised and then applied to a collection of 9,892 patients from 11 countries to create the Global MSSS. I…

AdultMalemedicine.medical_specialtyMultiple SclerosisDatabases FactualCross-sectional studyModels NeurologicalDiseaseSUSCEPTIBILITYSeverity of Illness IndexCohort StudiesDisability EvaluationPredictive Value of TestsRecurrenceSeverity of illnessmedicineHumansLongitudinal StudiesAge of OnsetModels StatisticalExpanded Disability Status Scalebusiness.industryMultiple sclerosisOUTCOME MEASUREReproducibility of ResultsNATURAL-HISTORYMiddle AgedPrognosismedicine.diseaseCross-Sectional StudiesPredictive value of testsDisease ProgressionPhysical therapyFemaleFranceNeurology (clinical)Age of onsetbusinessCohort study
researchProduct

Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy.

2004

Background: The key end point for treatment efficacy in chronic hepatitis C is absence of detectable virus at six months after treatment. However, the incidence of clinical events during long term follow up of patients with sustained virological response is still poorly documented and may differ between the Eastern and Western world. Aims: To assess clinical end points during long term follow up of European patients with a sustained virological response to interferon monotherapy. Methods: Meta-analysis of individual patient data from eight European protocolled follow up studies of interferon treatment for chronic hepatitis C. Results: A total of 286 sustained virological responders and 50 b…

AdultMalemedicine.medical_specialtyPlus ribavirinCirrhosisHepatocellular-CarcinomaAdolescentFibrosiPopulationAlpha interferonAntiviral AgentsSDG 3 - Good Health and Well-beingInternal medicinemedicineHumansDecompensationeducationSurvival analysisAgededucation.field_of_studyCirrhosibusiness.industryIncidence (epidemiology)Follow-upNatural-historyGastroenterologyCohortHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseSurvival AnalysisImpactTreatment OutcomeLiverHepatocellular carcinomaImmunologyRegression AnalysisFemaleTherapyInterferonsbusinessAlpha-interferonGut
researchProduct

Editor's Choice – Follow-up of Patients After Revascularisation for Peripheral Arterial Diseases: A Consensus Document From the European Society of C…

2019

International audience; Peripheral arterial diseases comprise different clinical presentations, from cerebrovascular disease down to lower extremity artery disease, from subclinical to disabling symptoms and events. According to clinical presentation, the patient's general condition, anatomical location and extension of lesions, revascularisation may be needed in addition to best medical treatment. The 2017 European Society of Cardiology guidelines in collaboration with the European Society for Vascular Surgery have addressed the indications for revascularisation. While most cases are amenable to either endovascular or surgical revascularisation, maintaining long-term patency is often chall…

Disease030204 cardiovascular system & hematology030230 surgeryPostoperative Complications0302 clinical medicineRestenosisRecurrenceSecondary Preventionfollow-upRandomized Controlled Trials as TopicUltrasonography Doppler Duplexmedicine.diagnostic_test3. Good healthEuropeSystematic reviewPractice Guidelines as TopicIN-STENT RESTENOSISCardiologyCardiology and Cardiovascular MedicineVascular Surgical ProceduresReoperationmedicine.medical_specialtyConsensusRevascularisationINFRAINGUINAL VEIN BYPASSMEDLINEPhysical examinationSTENOSIS03 medical and health sciencesrestenosisperipheral arterial diseaseInternal medicinemedicineHumansANGIOPLASTYVELOCITY CRITERIAbusiness.industryMagnetic resonance imagingNATURAL-HISTORYPerioperativeVascular surgery3126 Surgery anesthesiology intensive care radiologymedicine.diseaseDUPLEX ULTRASOUND SURVEILLANCEENDOVASCULAR TREATMENTRISK-FACTORSSurgery[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieCAROTID-ARTERYbusiness
researchProduct

Follow-up of patients after revascularisation for peripheral arterial diseases: a consensus document from the European Society of Cardiology Working …

2019

International audience; Peripheral arterial diseases comprise different clinical presentations, from cerebrovascular disease down to lower extremity artery disease, from subclinical to disabling symptoms and events. According to clinical presentation, the patient's general condition, anatomical location and extension of lesions, revascularisation may be needed in addition to best medical treatment. The 2017 European Society of Cardiology guidelines in collaboration with the European Society for Vascular Surgery have addressed the indications for revascularisation. While most cases are amenable to either endovascular or surgical revascularisation, maintaining long-term patency is often chall…

Epidemiologymedicine.medical_treatmentDiseaseFibromuscular dysplasia030204 cardiovascular system & hematology0302 clinical medicinefollow-up030212 general & internal medicineSocieties Medicalmedicine.diagnostic_test3. Good healthEuropeNatural historyTreatment OutcomeIN-STENT RESTENOSISCardiology030211 gastroenterology & hepatologyCardiology and Cardiovascular MedicineVascular Surgical Proceduresmedicine.medical_specialtyConsensusRevascularisationFIBROMUSCULAR DYSPLASIAINFRAINGUINAL VEIN BYPASSPhysical examinationRevascularizationSTENOSISrestenosis03 medical and health sciencesperipheral arterial diseaseInternal medicinemedicineHumansVELOCITY CRITERIAbusiness.industryNATURAL-HISTORYPerioperativeVascular surgery3126 Surgery anesthesiology intensive care radiologymedicine.diseaseStenosisDUPLEX ULTRASOUND SURVEILLANCEENDOVASCULAR TREATMENT3121 General medicine internal medicine and other clinical medicineRISK-FACTORSSurgery[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieCAROTID-ARTERYbusiness030217 neurology & neurosurgeryFollow-Up StudiesEuropean Journal of Preventive Cardiology
researchProduct

Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis

2013

To access publisher's full text version of this article click on the hyperlink at the bottom of the page Primary sclerosing cholangitis (PSC) is a severe liver disease of unknown etiology leading to fibrotic destruction of the bile ducts and ultimately to the need for liver transplantation. We compared 3,789 PSC cases of European ancestry to 25,079 population controls across 130,422 SNPs genotyped using the Immunochip. We identified 12 genome-wide significant associations outside the human leukocyte antigen (HLA) complex, 9 of which were new, increasing the number of known PSC risk loci to 16. Despite comorbidity with inflammatory bowel disease (IBD) in 72% of the cases, 6 of the 12 loci sh…

Linkage disequilibriumHISTONE DEACETYLASEGenotyping Techniquesendocrine system diseasesGenome-wide association studyDiseaseBioinformaticsLinkage Disequilibrium0302 clinical medicineGene FrequencyRisk FactorsOligonucleotide Array Sequence Analysis0303 health sciencesCrohn's diseaseeducation.field_of_studydigestive oral and skin physiologyCELIAC-DISEASEGenetic PleiotropyLifrarsjúkdómar3. Good healthFALSE DISCOVERY RATEULCERATIVE-COLITISgenetic association studydisease genetics030211 gastroenterology & hepatologySUSCEPTIBILITY LOCIPopulationCholangitis SclerosingSingle-nucleotide polymorphismHuman leukocyte antigenGENETIC RISKBiologyliverPolymorphism Single Nucleotidedigestive systemArticlePrimary sclerosing cholangitis03 medical and health sciencesFUNCTIONAL SIMILARITYGeneticsmedicineHumansGENOME-WIDE ASSOCIATIONeducation030304 developmental biologyNATURAL-HISTORYArfgengimedicine.diseasedigestive system diseasesimmunogeneticsGenetic LociCase-Control StudiesImmunologyGenome-Wide Association StudyINFLAMMATORY-BOWEL-DISEASE
researchProduct

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

2020

The exclusion of other chronic liver diseases including “excess” alcohol intake has until now been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD). However, given our current understanding of the pathogenesis of MAFLD and its rising prevalence, “positive criteria” to diagnose the disease are required. In this work, a panel of international experts from 22 countries propose a new definition for the diagnosis of MAFLD that is both comprehensive and simple, and is independent of other liver diseases. The criteria are based on evidence of hepatic steatosis, in addition to one of the following three criteria, namely overweight/obesity, presence …

Liver Cirrhosis0301 basic medicineCirrhosisDiagnostic criteriaCirrhosis; Diabetes; Diagnostic criteria; MAFLD; Metabolic; NAFLD; Obesity; Steatohepatitis[SDV]Life Sciences [q-bio]HISTOLOGIC FEATURESPROGRESSIONDiseaseTerminology0302 clinical medicineMedicine10. No inequalitySteatohepatitisNONALCOHOLIC STEATOHEPATITISFatty liverHIGH BLOOD-PRESSUREDiabetesHEALTHY OBESE3. Good healthPREVALENCECausalityCirrhosisDisease Progression030211 gastroenterology & hepatologymedicine.medical_specialtyConsensusMAFLDDIAGNOSIS03 medical and health sciencesMetabolic DiseasesTerminology as TopicDiabetes mellitusNAFLDMANAGEMENTHumansObesityIntensive care medicineHepatologybusiness.industryType 2 Diabetes MellitusNATURAL-HISTORYmedicine.diseaseFatty LiverClinical trial030104 developmental biologyDiabetes Mellitus Type 2MetabolicSteatohepatitisbusiness
researchProduct

Causes and place of death in Italian patients with amyotrophic lateral sclerosis

2010

Objectives - To determine the causes and place of death in a cohort of Italian patients with amyotrophic lateral sclerosis (ALS). A better understanding of the likely causes of death in ALS might improve the palliative care at the end-of-life, whereas knowing the place of death will help to verify the need for highly specialized care services, e.g. hospice and nursing home. Patients and methods - Between 2000 and 2008, 182 ALS patients (onset: spinal, 127; bulbar, 55; M/F: 1.6) were followed in a single ALS Tertiary Centre in Palermo, Sicily, Italy until death. Medical data for each individual patient were recorded in a large database throughout the disease course. Information concerning ca…

MaleDATABASEUNITED-STATESKaplan-Meier EstimateCohort StudiesResidence CharacteristicsCause of DeathHumansEPIDEMIOLOGYPOPULATIONAgedRetrospective StudiesChi-Square DistributionAmyotrophic Lateral SclerosisNATURAL-HISTORYMiddle AgedCAREALS death epidemiologyLIFEdeathsItalyENDSURVIVALSettore MED/26 - NeurologiaFemaleALSRespiratory Insufficiency
researchProduct

Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score An…

2020

INTRODUCTION: Patients with Crohn's disease experiencing endoscopic postoperative recurrence (POR) may benefit from antitumor necrosis factor (TNF) agents but scarce data on this are available. Our aim was to assess the efficacy of anti-TNF in improving mucosal lesions in patients with endoscopic POR. METHODS: Multicenter, retrospective, study of patients with Crohn's disease who underwent therapy with anti-TNF agents for endoscopic POR (Rutgeerts score > i1). Treatment outcomes were assessed by the findings in the last ileocolonoscopy performed after anti-TNF therapy was initiated. Endoscopic improvement and remission were defined as any reduction in the baseline Rutgeerts score and by a R…

Maleintestinal resectionrecurrent diseaseretrospective studyAnti-Inflammatory AgentsLogistic regressionGastroenterologyimmunology0302 clinical medicineCrohn DiseasepreventioncolonoscopyRecurrenceInterquartile rangeadalimumabIntestinal MucosariskCrohn's diseaseazathioprineMercaptopurinedrug effectGastroenterologyclinical trialColonoscopyTNF protein humanfemaleTreatment Outcomemesalazine030220 oncology & carcinogenesisintestine mucosaFemaleDrug Therapy Combination030211 gastroenterology & hepatologydouble-blindantiinflammatory agentImmunosuppressive Agentsmanagementmedicine.drugcombination drug therapyAdultmedicine.medical_specialtyAdolescentdiagnostic imagingtumor necrosis factormercaptopurineArticleYoung Adult03 medical and health sciencesInternal medicinemedicineAdalimumabHumanshumanproceduresPropensity ScoreRetrospective StudiestherapyTumor Necrosis Factor-alphabusiness.industryInflammatory Bowel DiseaseAdalimumabassociationnatural-historyOdds ratioimmunosuppressive agentmedicine.diseaseInfliximabInfliximabConfidence intervalmulticenter studyConcomitantpathologybusiness
researchProduct

Prognostic indicators in pediatric clinically isolated syndrome

2017

To assess prognostic factors for a second clinical attack and a first disability worsening event in pediatric clinically isolated syndrome (pCIS) suggestive of Multiple Sclerosis (MS) patients. Objective: To assess prognostic factors for a second clinical attack and a first disability-worsening event in pediatric clinically isolated syndrome (pCIS) suggestive of multiple sclerosis (MS) patients. Methods: A cohort of 770 pCIS patients was followed up for at least 10 years. Cox proportional hazard models and Recursive Partitioning and Amalgamation (RECPAM) tree-regression were used to analyze data. Results: In pCIS, female sex and a multifocal onset were risk factors for a second clinical att…

RegistrieMaleMultiple SclerosisAdolescentAdolescent; Age of Onset; Child; Demyelinating Diseases; Female; Follow-Up Studies; Humans; Male; Multiple Sclerosis; Prognosis; Retrospective Studies; Risk Factors; Disease Progression; Registries; Neurology; Neurology (clinical)PrognosiONSET MULTIPLE-SCLEROSISCHILDHOODCHILDRENPARACLINICAL FEATURESDISABILITY PROGRESSIONNOFollow-Up StudieRisk FactorsRetrospective Studieprognostic indicatorsMultiple Sclerosipediatric multiple sclerosis prognosis indicatorsHumansRegistriesAge of OnsetChildOPTIC NEURITISRetrospective StudiesRisk FactorDemyelinating DiseaseNATURAL-HISTORYPrognosismultiple sclerosis clinically isolated syndrome prognostic indicatorsNeurologyTRANSVERSE MYELITISclinically isolated syndromeINTERFERON BETA-1BDisease ProgressionSettore MED/26 - NeurologiaFemaleNeurology (clinical)FOLLOW-UPDemyelinating DiseasesFollow-Up StudiesHuman
researchProduct